The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients.

• Status: Withdrawn
• Trial end date: 2020-12-17
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the use of a drug called Gastrografin to aid in bowel mobility for paediatric patients who have undergone gastroschisis surgery. Gastroschisis is an abdominal wall birth defect where the bowel protrudes through a small opening beside the umbilicus. In these patients, the bowel is often less mobile due to its exposure outside of the body during fetal development. It is common for the bowel to be swollen and matted, which decreases motility and makes it increasingly difficult for the baby to have normal bowel function. Administering Gastrografin facilitates the entry of water into the intestines and bowel, which is thought to aid in bowel function and motility. This study will compare gastroschisis patients who received Gastrografin to gastroschisis patients collected as part of an ongoing observational study at our centre who did not receive Gastrografin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lawson Health Research Institute

Criteria

Inclusion Criteria:

• Diagnosis of gastroschisis

Exclusion Criteria:

• Gestational age less than 32 weeks

• Birth weight less than 1500 grams

• Definitive bowel atresia based on physician diagnosis